Pfizer's Direct-To-Consumer Model Faces Scrutiny From US Senators (CORRECTED)
Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...
Pfizer: Undervalued Safe Haven In Risk-Off Market
Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...
Zacks.com on MSN9d
Pfizer (PFE) Down 1.9% Since Last Earnings Report: Can It Rebound?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer: It's Time To Play Defensive
The market sentiment in the next few months is likely to be quite positive for Pfizer. Read why I maintain my strong buy ...
pharmaphorum13d
Bad news for Pfizer as blockbuster Xeljanz flunks safety study
JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and cancers added to its label in 2019. Now, a study designed to prove its safety ...
Healio2d
Pearl E. Grimes, MD, FAAD, honors mentor, reflects on 45 years of vitiligo advancements
John Kenney Jr., MD, Lifetime Achievement Award and Lectureship recipient Pearl E. Grimes, MD, FAAD, delivered a tribute to her predecessor as she discussed the history and advancements of vitiligo.
Nasdaq5d
Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold?
The Medicare Part D redesign under the Inflation Reduction Act (IRA) is also expected to hurt sales of Pfizer’s higher-priced drugs like Vyndaqel, Ibrance and Xeljanz in 2025. However ...